Researchers at Stanford Medicine have identified a potential breakthrough in treating osteoarthritis by inhibiting a protein known as 15-PGDH, which appears to drive cartilage degradation as joints age. According to a study published in the journal Science in 2024, blocking this protein successfully restored functional hyaline cartilage in aged mice and prevented the development of post-injury arthritis.
How 15-PGDH Affects Joint Health
The protein 15-PGDH acts as a "gerozyme," a class of proteins that accumulate with age and contribute to the decline of tissue function. According to the Stanford research team, levels of 15-PGDH approximately double in cartilage as mice age. This increase corresponds with the breakdown of collagen, the primary structural component of healthy joint cartilage. By inhibiting this protein, researchers observed that chondrocytes—the cells responsible for maintaining cartilage—shifted their gene expression back to a more youthful, regenerative state. Unlike previous regenerative therapies that relied on stem cells, this approach encourages existing cells to repair the tissue directly.
Potential for Human Osteoarthritis Treatment
Osteoarthritis affects roughly one in five adults in the U.S., creating an estimated $65 billion annual burden in direct healthcare costs. Current medical interventions are largely limited to pain management and surgical joint replacement. In experiments using human tissue samples collected during knee replacement surgeries, the 15-PGDH inhibitor effectively reduced the activity of genes linked to cartilage breakdown and promoted the generation of new articular cartilage.
Dr. Helen Blau, professor of microbiology and immunology at Stanford and a senior author of the study, noted that because 15-PGDH inhibitors are already being tested in clinical trials for age-related muscle weakness, the path toward human application for joint health may be accelerated.
Preventing Arthritis After Joint Injury
The study also examined the impact of 15-PGDH inhibition on joint injuries, specifically modeling ACL tears. According to the research, mice treated with the inhibitor twice weekly for four weeks following an injury were significantly less likely to develop osteoarthritis compared to untreated counterparts. Untreated mice showed a rapid spike in 15-PGDH levels and developed signs of arthritis within one month. The treated mice demonstrated improved mobility and weight-bearing capability on the injured limb, suggesting that the treatment could serve as a preventative measure for athletes or individuals who suffer joint trauma.
Current Status of Research
While the findings are promising, the application remains in the experimental stage. The researchers hold patent applications related to 15-PGDH inhibition for tissue rejuvenation, and the technology has been licensed to Epirium Bio.
Key findings from the Stanford study include:
- Regeneration: The treatment promoted the growth of hyaline cartilage, which is the smooth, slippery tissue necessary for pain-free joint movement.
- Mechanism: The drug functions by increasing levels of prostaglandin E2, a molecule that, at normal biological levels, supports the repair of bone, nerve, and muscle tissue.
- Safety: Preliminary Phase 1 clinical trials for muscle-related applications indicate the inhibitor is well-tolerated in humans, providing a foundation for future studies on cartilage repair.
The team’s next steps involve launching clinical trials to confirm these results in humans, with the long-term goal of providing a non-surgical alternative to joint replacement procedures.